Press release
Waldenstrom's Macroglobulinaemia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Amgen, Abbvie, Roche, TransThera, BeiGene, Janssen, Ascentage, Gilead, InnoCare Pharma, Mustang Bio
"Waldenstrom's Macroglobulinaemia Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Waldenstrom's Macroglobulinaemia Therapeutics Market.
The report provides a detailed description of the Waldenstrom's Macroglobulinaemia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Waldenstrom's Macroglobulinaemia Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Waldenstrom's Macroglobulinaemia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Waldenstrom's Macroglobulinaemia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Waldenstrom's Macroglobulinaemia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Waldenstrom's Macroglobulinaemia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Waldenstrom's Macroglobulinaemia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Waldenstrom's Macroglobulinaemia Therapeutics Domain:
https://www.delveinsight.com/report-store/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Waldenstrom's Macroglobulinaemia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Waldenstrom's Macroglobulinaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Request for Sample PDF to Understand More About the Waldenstrom's Macroglobulinaemia Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Waldenstrom's Macroglobulinaemia Therapeutics Analysis
There are approx. 20+ key companies developing the therapies for Waldenstrom's Macroglobulinaemia. Currently, Ascentage Pharma is leading the therapeutics market with its Waldenstrom's Macroglobulinaemia drug candidates in the most advanced stage of clinical development.
Waldenstrom's Macroglobulinaemia Companies in the Therapeutics Market Include:
• Amgen
• Abbvie
• Roche
• Bristol-Myers Squibb
• X4 Pharmaceuticals
• TransThera Sciences
• BeiGene
• Janssen
• Ascentage Pharma
• Gilead Sciences
• ADC Therapeutics
• InnoCare Pharma
• Mustang Bio
And many others
Emerging and Marketed Waldenstrom's Macroglobulinaemia Therapies Covered in the Report Include:
• Lisaftoclax: Ascentage Pharma
• ABT199: Abbvie
• TT-01488: TransThera Biosciences
And Many More
Get an in-depth Assessment of the Emerging Therapies and Waldenstrom's Macroglobulinaemia Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Waldenstrom's Macroglobulinaemia Current Treatment Patterns
4. Waldenstrom's Macroglobulinaemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Waldenstrom's Macroglobulinaemia Late-Stage Products (Phase-III)
7. Waldenstrom's Macroglobulinaemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Waldenstrom's Macroglobulinaemia Discontinued Products
13. Waldenstrom's Macroglobulinaemia Product Profiles
14. Waldenstrom's Macroglobulinaemia Companies
15. Waldenstrom's Macroglobulinaemia Drugs
16. Dormant and Discontinued Products
17. Waldenstrom's Macroglobulinaemia Unmet Needs
18. Waldenstrom's Macroglobulinaemia Future Perspectives
19. Waldenstrom's Macroglobulinaemia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/waldenstroms-macroglobulinaemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market
Narcolepsy Market
https://www.delveinsight.com/report-store/narcolepsy-market
Osteoporosis Market
https://www.delveinsight.com/report-store/osteoporosis-market
Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market
Migraine Market
https://www.delveinsight.com/report-store/migraine-market
Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market
Substance use disorder Market
https://www.delveinsight.com/report-store/substance-use-disorder-market
Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market
Campylobacter Infections Market
https://www.delveinsight.com/report-store/campylobacter-infections-market
mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market
Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market
Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
Obsessive-Compulsive Disorder Market
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market
Diabetic Eye Disease Market
https://www.delveinsight.com/report-store/diabetic-eye-disease-market
Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
Hernia Repair Devices Market
https://www.delveinsight.com/report-store/hernia-repair-devices-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Waldenstrom's Macroglobulinaemia Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Amgen, Abbvie, Roche, TransThera, BeiGene, Janssen, Ascentage, Gilead, InnoCare Pharma, Mustang Bio here
News-ID: 3134187 • Views: …
More Releases from DelveInsight Business Research LLP
Lupus Nephritis Clinical Trial Pipeline Appears Robust With 35+ Key Pharma Compa …
DelveInsight's "Lupus Nephritis Pipeline Insight 2026" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lupus Nephritis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Cushing Syndrome Clinical Trial Pipeline Shows Potential with Active Contributio …
DelveInsight's "Cushing Syndrome Pipeline Insight 2026" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cushing Syndrome Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
Alzheimer's Disease Clinical Trial Pipeline Gains Momentum: 200+ Companies Lead …
DelveInsight's, "Alzheimer's Disease Pipeline Insight 2026" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Alzheimer's Disease…
Nontuberculous Mycobacterial Market Size in the 7MM is projected to grow at a si …
DelveInsight's "Nontuberculous Mycobacterial Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Nontuberculous Mycobacterial, historical and forecasted epidemiology as well as the Nontuberculous Mycobacterial market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Nontuberculous Mycobacterial Market by downloading the comprehensive report from DelveInsight @ Nontuberculous Mycobacterial Treatment Market Size- https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
More Releases for Waldenstrom
United States Waldenstrom Macroglobulinemia Market Size, Share, Trends - Exclusi …
"Waldenstrom Macroglobulinemia market is estimated to reach at a high CAGR during the forecast period 2024-2031." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/waldenstrom-macroglobulinemia-market?sp
United States: Recent Industry Developments
✅ In July 2025, Cellectar Biosciences announced the US FDA granted Breakthrough Therapy Designation for iopofosine I 131 in Waldenstrom macroglobulinemia. This designation accelerates the development and review of this promising targeted radiopharmaceutical therapy.…
Waldenstrom Macroglobulinemia Market Positioned for Accelerated Development Thro …
DelveInsight's "Waldenstrom Macroglobulinemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the Waldenstrom Macroglobulinemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Waldenstrom Macroglobulinemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Waldenstrom Macroglobulinemia Market Forecast
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Waldenstrom Macroglobulinemia Market to Reach US$ 229.1 Million by 2033
Market Overview:
The waldenstrom macroglobulinemia market reached a value of US$ 146.0 Million in 2022 and expects to reach US$ 229.1 Million by 2033, exhibiting a growth rate (CAGR) of 4.17% during 2023-2033.
According to the IMARC Group, the waldenström macroglobulinemia market exhibited a market size of US$ 229.1 Million in the year 2033 and is projected at a CAGR of 4.17% during 2023-2033. This can be attributed to the emerging popularity…
Waldenstrom Macroglobulinemia Therapeutics Market Sluggish Growth Rate Foreseen …
The Waldenstrom Macroglobulinemia Therapeutics Market size is expected to grow at an annual average of CAGR 4% during the forecast period (2023-2029). Waldenstrom macroglobulinemia (WM) is a rare blood cell cancer characterized by the production of large amounts of an abnormal protein (called macroglobulin) by cancer cells. WM is a type of non-Hodgkin lymphoma (NHL) and is also known as lymphoplasmacytic lymphoma. WM is a low-grade B cell lymphoproliferative neoplasm…
Waldenstrom Macroglobulinemia Treatment Market Business Opportunities Forecast t …
According to Precision Business Insights (PBI), latest report, the waldenstrom macroglobulinemia treatment market size was valued at USD 163.7 million in 2022 and is expected to grow at a CAGR of 6.7% during the forecast period 2023 to 2029. The primary factors that drive the market are the growing prevalence of white blood cell lymphoma among geriatric people, rising in new treatment therapies, and the increasing demand for novel drugs…
Waldenstrom Macroglobulinemia Market Report- Statistical Analysis, Business Oppo …
The Waldenstrom Macroglobulinemia Market research report segments the market based on type, applications, end-users, and different geographies. Waldenstrom Macroglobulinemia Market helps new entrants/ stakeholders to understand the market trends and plan robust market strategies. Moreover, Waldenstrom Macroglobulinemia Market report also offers a covid-19 impact on the Waldenstrom Macroglobulinemia Market, enabling businesses to understand market drivers and restraints.
Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5154352
Waldenstrom Macroglobulinemia Market provides an overview…
